Tech-enabled drug discovery company Insilico Medicine secured $110 million in an oversubscribed Series E funding round.
A large equity fund of Value Partners Group, an asset management firm in Asia, and new and existing investors participated in the round.
WHAT IT DOES
Massachusetts-based Insilico's proprietary generative AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific...
